Immunogen, Inc.

NASDAQ:IMGN   4:00:00 PM EDT
5.30
-0.13 (-2.39%)
7:40:36 PM EDT: $5.26 -0.04 (-0.76%)
Products

ImmunoGen Announces FDA Accelerated Approval Of ELAHERE For The Treatment Of Platinum-Resistant Ovarian Cancer

Published: 11/14/2022 22:47 GMT
Immunogen, Inc. (IMGN) - Immunogen Announces FDA Accelerated Approval of Elahere™ (mirvetuximab Soravtansine-gynx) for the Treatment of Platinum-resistant Ovarian Cancer.
Immunogen Inc - Elahere Indication Covers Patients With One to Three Prior Systemic Treatment Regimens, Regardless of Prior Avastin(®) Use.